With the Processing License from Health Canada in place, NordicCan is ready to start production of CBD products in Canada.
“With the Processing License granted by Health Canada, we are ready to go into full-scale production beginning 2022 at our site, Cogent, located near Vancouver”, says NordicCan CEO Julie Malbaek. “Since we received our Research License in February 2021, we have refined our formulations and production capabilities so that we are now ready with high quality formats that meet the increasing demand for user-friendly and pleasurable CBD products for the health and wellness segments.”
NordicCan specializes in CBD gums, lozenges, sublingual tablets and other oral unit-dose formats that appeal to the growing market for cannabinoids.
“As part of the Fertin Group, we draw upon the extensive experience in developing and manufacturing oral and intra-oral delivery formats that meet global quality standards. Patenting is a key strategy, which protects our customers’ rights to launch and sell novel CBD product formats in the market place”, says Julie Malbaek.
NordicCan’s manufacturing facility, Cogent, is built to meet all standards related to CBD production in the North American market.